Management of patients with uncontrolled arterial hypertension - the role of electronic compliance monitoring, 24 hour ambulatory blood pressure monitoring and candesartan/hydrochlorothiazide (HCTZ)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN02311110

Enrollment

Registered

2006-07-26

Start date

2001-01-02

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant arterial hypertension Circulatory System Hypertension

Interventions

Patients with oBP of more than 140/90 mmHg despite combination therapy were begun on microelectromechanical systems (MEMS) monitoring and self BP measurement for four weeks of run-in. Of 62 such pati

in the remaining 44 still uncontrolled patients, candesartan/HCTZ was substituted for one of the combination therapy drugs, with half these patients receiving passive compliance monitoring (Group B) a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with essential hypertension and office Blood Pressure (oBP) more than or equal to 140/90 mmHg, despite combination therapy (more than two antihypertensive drugs)

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Known intolerance of HCTZ or Angiotensin II Type One Receptor Blockers (AT1-Blockers) 3. Secondary hypertension

Design outcomes

Primary

Measure	Time frame
1. Drug compliance 2. Blood pressure	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026